Life Sciences

The overall research objective was to capture and analyze global next-generation (NGS) sequencing trends and use. Most researchers outsource NGS technologies; however, in-house NGS technology use is expected to increase within the next 12 months. Data accuracy and operating costs are the top criteria for purchasing sequencing instruments. Disease-r...

The standard of care, microfracture, does not fulfill long-term needs for patients with chondral defects. In addition, current alternative treatment options are plagued by multiple challenges and limitations. This research service focuses on medicine in the knee cartilage repair market, providing a detailed overview of 9 key products. A product an...

This research service provides the market revenues and trends of various breast imaging modalities in the Chinese market. Increasing incidence of breast cancer, awareness among the population, healthcare reforms, and expansion of breast screening to rural areas accelerate the growth of breast imaging market in China. Increasing disposable income, ...

This analysis of the US enterprise medical image viewers market provides an overview of the current and future information technology (IT) ecosystem for imaging informatics with enterprise viewers in context. The study presents and discusses the various market segments for enterprise viewers, the key customers for each type of solution as well as t...

The Malaysia healthcare outlook addresses the investment opportunities across various segments. The study explores the developments in the hospital industry, IVD and POCT industry, pharmaceutical industry, biotechnology industry, medical devices industry, connected health industry, and the aged care industry in the country. The study explores oppor...

This issue of Vital Signs, released on August 5, 2014, discusses the Senators plead to the FDA for the quick action regarding draft guidance on laboratory developed tests (LDTs), Synthetic Biologys Series A funding round, Roches investment in Stratos Genomics, and Indias cap on drug prices.

This issue of Vital Signs, released on July 24, 2014, discusses emerging pharma trends in the Asia Pacific and how the region will act as an anchor to global pharma in coming years, especially in segments such as manufacturing, R&D and clinical trials.

Despite global economic and industry challenges, in vitro diagnostics (IVD) markets are growing robustly at double the rate of the global pharmaceutical industry. The global IVD market size was $47.30 billion in 2013; it is expected to reach $62.63 billion in 2017, at a compound annual growth rate of 7.3%. Because of stagnating mature markets, comp...